Precision Medicine Exeter Innovation Platform (PMEI Platform)
Lead Research Organisation:
UNIVERSITY OF EXETER
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Publications
Ammous Z
(2021)
A biallelic SNIP1 Amish founder variant causes a recognizable neurodevelopmental disorder.
in PLoS genetics
Anayo L
(2018)
An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
in Lasers in surgery and medicine
Bokori-Brown M
(2018)
Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
in Frontiers in Oncology
Curnow A
(2019)
Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
in Photodiagnosis and photodynamic therapy
Fasham J
(2023)
SLC4A10 mutation causes a neurological disorder associated with impaired GABAergic transmission
in Brain
Fasham J
(2022)
Elucidating the clinical spectrum and molecular basis of HYAL2 deficiency.
in Genetics in medicine : official journal of the American College of Medical Genetics
Fasham J
(2020)
No association between SCN9A and monogenic human epilepsy disorders.
in PLoS genetics
Khalaf-Nazzal R
(2022)
Bi-allelic CAMSAP1 variants cause a clinically recognizable neuronal migration disorder.
in American journal of human genetics
Khalaf-Nazzal R
(2021)
Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia.
in Brain sciences
Leslie JS
(2022)
Biallelic DAW1 variants cause a motile ciliopathy characterized by laterality defects and subtle ciliary beating abnormalities.
in Genetics in medicine : official journal of the American College of Medical Genetics
| Description | A biophysical approach to identify genes underlying antibiotic tolerance |
| Amount | £20,000 (GBP) |
| Funding ID | RGS\R2\18007 |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 10/2019 |
| Description | CASE Studentship - Neurophysiological actions of incretins in the aging CNS |
| Amount | £125,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Developing a long lasting legacy of improved health and educational outcomes stemming from genetic research findings in the Amish |
| Amount | £30,000 (GBP) |
| Funding ID | MRF-145-0003-DG-BAPLE |
| Organisation | Medical Research Council (MRC) |
| Department | Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2018 |
| Description | Dissemination Award - Development of an online educational resource focussed on the benefits of a community approach to genomic medicine and research |
| Amount | £30,000 (GBP) |
| Funding ID | MRF-145-0005-DG-BAPLE |
| Organisation | Medical Research Council (MRC) |
| Department | Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2019 |
| Description | Dr. Stefano Pagliara: Funding to organise a symposium on "Microfluidics and mathematical modelling for understanding cellular heterogeneity". Hummingbird Bioscience has been invited to participate to the symposium to foster the current collaboration. |
| Amount | £12,500 (GBP) |
| Organisation | GW4 |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 07/2018 |
| Description | External Collaboration, Innovation and Entrepreneurism: Translational Medicine in Exeter (EXCITEME) |
| Amount | £18,652 (GBP) |
| Funding ID | MC_PC_16072 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 08/2018 |
| Description | Formation of synthetic blastocysts by self-organization of human naïve pluripotent stem cells |
| Amount | £553,056 (GBP) |
| Funding ID | BB/V017128/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 08/2025 |
| Description | Internally funded MSc Research Project |
| Amount | £0 (GBP) |
| Organisation | University of Exeter |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | MRC studentship from GW4 DTC |
| Amount | £90,000 (GBP) |
| Organisation | GW4 |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2018 |
| Description | PhD studentship - Developing microfluidic platforms to fight bio-threats |
| Amount | £82,000 (GBP) |
| Funding ID | 1920457 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Reducing inequalities in global healthcare provision through effective research dissemination |
| Amount | £30,000 (GBP) |
| Funding ID | MRF-145-0006-DG-BAPL-C0788 |
| Organisation | Medical Research Council (MRC) |
| Department | Medical Research Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Ultra-High-Throughput Directed Evolution of Antimicrobials using Droplet Microfluidics. PhD in Physics and Astronomy |
| Amount | £149,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Title | A global approach to genetic based specific carrier testing and newborn screening |
| Description | West Bank Palestinian sequencing data |
| Type Of Material | Data handling & control |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | West Bank Palestinian sequencing data |
| Title | Angela Shore - Intra-operative tissue blood flow imaging in breast reconstruction following mastectomy (observational pilot study) |
| Description | As part of the objectives of the project, the collected data was used to contribute in deriving clinically relevant viability thresholds to indicate surgically operated tissue that is at risk of developing post-operative complications. |
| Type Of Material | Data analysis technique |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | This will enable the development and validation of critical aspects of the software for routine surgical application and to enhance the clinical ease and relevance of data interpretation to aid intra-operative surgical decisions during free-flap breast reconstructions. |
| Title | Pakistan and Oman sequencing data |
| Description | Population specific databases of aggregated whole exome sequencing data have been developed for Pakistan and Oman |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Still active |
| Description | A global approach to genetic based specific carrier testing and newborn screening |
| Organisation | Health Services Laboratories |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | -In order to carry out this work the group required the dedicated time of a Post-Doctoral Research Fellow for 4.5 months FTE. -Consumable support was required for test development in Exeter including newborn testing filter paper cards, DNA extraction kits and reagents, DNA sequencing kits and sequencing costs, general plastic ware costs, general laboratory consumables (eg electrophoresis reagents and consumables, buffers and reagents etc). -Collaborative travel for meetings with HSL representatives. This includes travel relating to meetings within the UK to hold project-related discussions, as well as travel for the applicants and HSL partners to meeting with overseas collaborators and potential local providers to identify the unmet diagnostic need locally and define the potential market. -UoE college provided salary costs for Prof Crosby and Dr Baple for time spent on this project, as well as directly allocated costs including estates, infrastructure and indirect costs. |
| Collaborator Contribution | Contributions included HSL consultancy costs, HSL community liaison costs, and HSL travel/subsistence costs. |
| Impact | -Completed second stage validation of PA newborn testing using our newly developed genetic testing methodology. -Extension of the newborn test to include 15 additional conditions where early diagnosis and management has been demonstrated to improve healthcare outcomes. -Extension of newborn testing to provide the framework for a similar approach to testing in other UK and international patient subgroups by identifying the unmet or poorly understood diagnostic need. This will enable expansion to include additional relevant conditions extending the market potential for the product. -Developing the methodology to facilitate point of access preconception and premarital carrier testing. |
| Start Year | 2016 |
| Description | AstraZeneca - Student Masterclass - M Hetheridge |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Arranging an extension to the previously successful pilot student workshop with AstraZeneca to improve student understanding of and access to industry. The students will present to AZ at the end of the masterclass week on what they have seen during their week visiting the various sites. |
| Collaborator Contribution | Eight students from the University of Exeter will attend a one week multi-site, multi-discipline experience with AstraZeneca; the visit will include scientific and chemistry lab tours, discussions and presentations on innovative medicines, marketing for AZ at the Diabetes UK Congress, and presentations and networking with a number of AZ professionals across a number of science and medicines-related areas including Medical & Healthcare Affairs, Future Pipeline, Regulatory and Learning & Development. |
| Impact | This 'Student Masterclass', now in its second year (with further commitment from AstraZeneca to a third) saw students from our Medical Sciences course visit the company's different departments over a consecutive 7 day period, providing them insight into various business and research activities. This initiative is valued by both sides as it incorporates more human resource and training activities, including talent recruitment and student supervision. AstraZeneca continues to contribute towards the travel and accommodation costs as well as providing a considerable in-kind contribution in staff time across several departments. |
| Start Year | 2017 |
| Description | Development of in vivo CNS imaging methods for the study of vascular endpoints in neurological disease |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A student from the Randall research group will engage in a placement at the industry partner Eli Lilly where they will receive training from Lilly staff and run two short pilot projects investigating dementia-associated brain pathology in the mouse models used by Lilly for their drug discovery work. This pilot data and learning from the placement will then be transferred back to Randall's Biomedical Neuroscience group at Exeter where a new imaging system will be functioning. We will then continue the project in collaboration with Eli Lilly and also transfer the methodological learning to others. |
| Collaborator Contribution | Eli Lilly will provide the transgenic disease model experimental animals used for the training and experiments during the placement. Lilly will also provide staff time to carry out training and all consumables required for surgery and imaging including any viral constructs used to deliver imaging substrates to the CNS parenchyma. Lilly will provide access to their state of the art in vivo 2 photon imaging microscope. Lilly will also contribute to accommodation costs during the placement. |
| Impact | Ultimately we completed the experimental arms and much of the analysis (including key endpoints) for 2 studies of how pivotal dementia pathologies impact the integrity of the blood brain barrier. As the end of the funded period Lilly funded an additional 2 months placement as this was deemed mutually highly beneficial to the collaborative project- importantly this resulted in additional training opportunities in X-clarity based tissue clearing methodology. I have purchased the equipment to do this in Exeter so we can rapidly transfer Judith's learning to a wider group now she is back with us. There has been make interest and take up of the opportunities this provides. The secondee now has all the skills required to allow us to do in house in vivo 2P imaging when our in house system is finally delivered in 1Q2018. Her skills will be crucial to enabling these technologies rapidly at Exeter, especially as the Randall lab's other post-doc who learnt this at Lilly left in 4Q 2017 for a faculty post elsewhere. Notably our soon to arrive (Wellcome Trust funded) 2 photon imaging system has greater functionality than the one at Lilly we accessed through this award. We also have a new lightsheet microscope that we believe can image whole cleared brains for additional routes to the study of the vasculature in CNS disease. We aim to make these enhanced imaging capabilities available to Lilly to grow our work together. One route to this may be through their internal "precompetive research" post-doctoral programme. Lilly will continue to supply us with disease model mice they have breed and this continues to aid various aspects of our work together and is not without considerable value. We are now developing an improved analysis pipeline and are also in (very) early stage discussions with an Exeter spin-out company in the image processing area around data processing of this nature. This work has strengthened our already well-developed Lilly links and we will seek to grow this area of work via the BBSRC collaborative training partnership awarded to Lilly, Exeter and Kings London that has 12 PhD positions available over 3 recruitment rounds. We have made one presentation of the initial data and a second will be made in London in March 2018. We are planning one or two papers - likely journal eNeuro or Neuroimage. |
| Start Year | 2016 |
| Description | Establishment of a single cell isolation platform for identification of heavy and light chains in the antibody repertoire |
| Organisation | Hummingbird Bioscience Pte. Ltd |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Antibodies are highly specific and a promising avenue to be used for drug treatment. However, the screening of antibodies is cumbersome, expensive and requires in vivo rodent models. This is due to the fact that an antibody is made up by two different genes the heavy (VH) and light (VL) chain, the combination of which differs in each individual B-cell. The holy grail of antibody discovery is to identify the combination of VH and VL in individual B cells. A novel game changing approach combines microfluidic B-cell isolation, amplification, barcoding of the VH and VL regions followed and long-read sequencing. Exeter will implement a single-cell isolation platform to isolate the VH-VL pairs from single cells and sequence them in its long-read sequencing facility. Hummingbird Bioscience will be able to use the resulting data to clone the discovered VH-VL pairs to enhance the stability, affinity an efficacy of antibodies used in cancer therapeutics targeting the EGFR family of receptor tyrosine kinases. |
| Collaborator Contribution | Hummingbird will provide funding to facilitate visits between University of Exeter and Hummingbird staff to both facilities during the project as well as funding to support training for a UoE post-doc to learn about the RT-PCR linkages steps. Hummingbird Bioscience will provide an in-kind contribution for consumables and equipment and staff time, to provide experimental and analytical support. |
| Impact | Further Funding Hummingbird Bioscience has contributed with a further £3,000 for the project (above the £50k already provided) and we are currently exploring joint bids such as MRC CASE studentships and BBSRC Industrial partnership awards. Furthermore, the developed platform will be valuable for research ongoing in other groups. In this respect, Prof. Jon Mill has just been awarded a MRC Fellowship and will take advantage of this platform to investigate single cell transcriptomics. Moreover, Dr Fabrice Gielen, a newly recruited research fellow in the LSI, will contribute to the further development of this platform and take advantage of the data already obtained, for his research on directed evolution that is likely to generate further bids to the MRC. Gained Expertise Dr Jeremie Poschmann has acquired a new skill set including microfluidics, microscopy and single-cell isolation, that will be valuable for the continuation of his career. In April 2017 Dr Poschmann has taken over an academic position in France and we have recruited Dr Aaron Jeffries on the project. As a consequence he has also acquired considerable knowledge of this cutting-edge technology expanding his repertoire of single-cell analysis skills. - The developed platform will be of interest to cellular biologists, microbiologists, ecologists and evolutionary biologists at Exeter and within the GW4 alliance, specifically those researchers working on heterogeneous clonal or mixed microbial populations. The developed platform will be presented to the scientific community through meetings and seminars at the national and international level. |
| Start Year | 2016 |
| Description | Intra-operative tissue blood flow imaging in breast reconstruction following mastectomy (observational pilot study) |
| Organisation | Moor Instruments Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The aim of the collaboration is to develop a new intra-operative tissue blood flow imaging (IoTBFI) system based on the Laser Speckle imaging technique that enables intra-operative, real time, non-invasive mapping and assessment of tissue blood flow as an aid to surgical decision making in the selection and use of tissue for breast reconstruction. The central role of the UoE researcher will involve coordinating the day-to-day running of the project onsite and contributing to overall project management. The researcher will work closely with the industry partner, Moor Instruments, to help with developing and refining the required modifications to LSI system and its software for use in surgery. The researcher will play a major role in setting up the study, gaining ethics, creating and maintaining essential study documents. |
| Collaborator Contribution | In kind contributions will be provided by Moor Instruments to cover the lease costs of the Laser Speckle Imaging system with its prototype IoTBFI modifications, its associated computer and the mobile stand of the imager for the duration of the project. Moor Instruments will contribute the consumable costs of 25 single use sterile covers for the imager to be used in surgery and a cash contribution of £6000 will also be provided to support the proposed project activities. |
| Impact | a. Plans for further funding are currently under consideration with all partners from the project. We are currently at the data analysis stage to prepare for future funding applications to expand on the work resulting from this project and progress to interventional studies/clinical trials; b. A manuscript of the initial work that this project was based on has been submitted to the Journal of Microsurgery for consideration, it is planned that the data obtained from this project will contribute to the preparation of a second manuscript for submission to a clinical or academic journal in the near future; c. The members of our research group have expanded our knowledge and gained further insights into the required modifications and the potential applications of loTBFI in free flap breast reconstruction under different surgical scenarios. Our sole researcher in the operating theatre has gained expertise in facilitating and supporting current and new members of the surgical and medical team to integrate the use of IoTBFI in the operating theatre during the surgery. The researcher has also benefited from the expanded knowledge and experience gained from the project that allowed our research group to build stronger collaborations with the surgical team in Exeter and with Moor Instruments for future projects; d. We have been able to engage with new surgical and medical staff throughout the project especially when the practical work of the study was performed in the operating theatre. We were given an opportunity to deliver a PowerPoint presentation followed by an open discussion about the project in a regular teaching session at the hospital. In which, we were able to engage with a wide range of different members from the surgical team to support and to get involved in the project; e. The study was an observational study and therefore it is too early to influence policy; f. IP is being considered by the industrial external partner, Moor Instruments, within the context of results and observations made during the project (please see g, below); g. During this project ideas have been developed on methods to derive viability thresholds that will enable interventional studies/clinical trials after sufficient cases have been assessed. This will enable the development and validation of critical aspects of the software for routine surgical application. |
| Start Year | 2016 |
| Description | Maximising Novel Photodynamic Therapy Cancer Drug Development |
| Organisation | Photocure |
| Country | Norway |
| Sector | Private |
| PI Contribution | Non-melanoma skin cancer (NMSC) is the most common form of cancer worldwide. Effective, cosmetically-acceptable treatments are therefore essential. Photodynamic therapy (PDT) uses light to activate a pre-administered drug to kill skin cancers without harming healthy cells, so healing occurs without scarring. PDT is effective against superficial NMSC, however ~50% of lesions are too thick to be treated with the current treatment protocol. University of Exeter's A Curnow has synthesised a more effective form of iron-chelating PDT drug (AP2-18); the full potential of which will be determined experimentally during this project prior to entering clinical license negotiations with our commercial partner. The main cost that will be incurred is the salary of the Post-doctoral Research Fellow required full-time to undertake the specified experimentation (for the period of 12 months). At the current time the Clinical Photobiology research team does not have a member of staff employed at this grade or with the necessary skill set to undertake research of this commercial importance within their laboratory. Dr Curnow is also employed to spend 80% of her working week on educational activity and so is not able to complete this experimental programme personally within her laboratory. In addition £2,500 is requested for the consumables/chemical purchase required to synthesise the novel AP2-18 compound by CLES (Streatham). A further £9,500 is being requested to cover the purchase of the new cell types required for this project plus the project specific experimental costs associated with this investigation in Cornwall (e.g. confocal microscopy plates, tissue culture consumables etc.), which due to their sterility and precise specifications are relatively expensive in consumable terms (~£600 per month). |
| Collaborator Contribution | CONFIDENTIAL - Associated costs with the project amount to £52.5K of in-kind contributions. |
| Impact | Through this project, the Postdoctoral Research Fellow appointed has generated more detailed information about the PDT action of the novel compound AP2-18. This will allow our discussions with new potential commercial partners to be better informed and evidenced. Further publication standard data has also been produced, which we will be able to publish in due course (when deemed commercially appropriate). |
| Start Year | 2016 |
| Description | Understanding the mechanism of Pseudomonas exotoxin (PE)-based immunotoxin (IT)-induced haemolytic uremic syndrome (HUS) and vascular leak syndrome (VLS) |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | To investigate the mechanisms of Pseudomonas exotoxin (PE)-based immunotoxin (IT)-induced vascular leakage and haemolysis that may lead to refinements of administration protocols or the development of support measures to alleviate the side effects of PE-IT treatment. In the longer term this work might guide the development of new carrier toxins for immunotherapy. |
| Collaborator Contribution | MedImmune is providing funding toward a post-doctoral researcher for a period 12 months to a value of £73,942 and will supply immunotoxins as required in the project. |
| Impact | We have characterised the effects of HA22 immunotoxin on vascular permeability on excised human mesenteric artery sections • Measurements of membrane dipole potential and absorption of 415 nm light indicate that HA22 immunotoxin interacts with red blood cells, and this interaction is via the toxin component of HA22 • We observed variability in response to HA22 treatment between Acute Lymphoblastic Leukaemia patients using absorption of 415 nm light measurements, indicating that these measurements could identify patients at risk of developing haemolytic uremic syndrome (HUS) Future studies • Characterise the effects of HA22 on vascular permeability in perfused human mesentery/omental tissue • Bring together vascular studies and blood cell measurements by investigating the effects of HA22-induced vascular endothelial damage on red blood cell lysis. This may reveal commonalities and synergies between VLS and HUS. • Investigate the molecular mechanisms of HA22 action on the vasculature by immunohistochemistry of excised mesenteric arteries. • Measure the membrane surface potential of RBCs from the fluorescence of fluorescein-phosphatidylethanolamine (FPE) incorporated into the outer leaflet of the blood cell membrane; also likely to be a determinant of the primary interaction between HA22 and the plasma membrane. • Investigate binding of fluorescently labelled HA22 to the plasma membrane of red blood cells (RBCs) Papers on effects of immunotoxin on vascular permeability and on red cells are in preparation. Awaiting responses from company before formulating strategy for further funding. |
| Start Year | 2016 |
| Title | 'moorFlo' trademark - Angela Shore |
| Description | Moor has registered a 'moorFlo' trademark and a patent application for image processing techniques is under active consideration. An agreement is in place regarding royalties. There is copyright protection on prototype software designed and produced by Moor (prior to the P2D grant project). |
| IP Reference | |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | TBC |
| Title | PYRIDINONE COMPOUNDS FOR USE IN PHOTODYNAMIC THERAPY |
| Description | A compound which is a compound of formula (I) or any salt thereof: wherein R1 is a Ci-C6 alkyl group, R2 is H or a Ci-C6 alkyl group, R3 is H or a Ci-C6 alkyl group, and n is an integer from 0 to 5. |
| IP Reference | WO2014033477 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | The potential commercial value of the IP associated with this novel photodynamic therapy cancer drug is significant and so we shall now seek a new commercial partner to undertake more clinical development of this novel compound. |
| Title | Angela Shore - Intra-operative tissue blood flow imaging in breast reconstruction following mastectomy (observational pilot study) |
| Description | As part of the primary outcomes of the project, results from this study have enabled the development of a new intra-operative tissue blood flow imaging system based on the LSI technique. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Impact | This new system enables intra-operative, real time, non-invasive mapping and assessment of tissue blood flow as an aid to surgical decision making in the selection and use of tissue for breast reconstruction, and for further assessments of free flap viability. |
| Description | BBC Radio 4 Inside Science |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Baple and Prof Crosby were featured on BBC Inside Science (BBC Radio 4), "Genetic diseases in Amish communities" discussing their Windows of Hope project with Anabaptist communities in North America. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.bbc.co.uk/programmes/m000dgbt |
| Description | Poster at the 17th International Photodynamic Association World Congress (Boston) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster at the 17th International Photodynamic Association World Congress (Boston July 2019) and the accompanying Conference Proceedings: C. Reburn, L. Anayo, A. Magnussen, A. Perry, M. Wood and A. Curnow. Experimental findings utilising a new iron chelating ALA prodrug to enhance protoporphyrin IX-induced photodynamic therapy. SPIE Conference Proceedings, 17th International Photodynamic Association World Congress: 2019;11070:110706R (7 pages) |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://spie.org/PDT/conferencedetails/17th-international-photodynamic-association-world-congress?SS... |
| Description | School Visit (Exeter) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Data used in engagement presentation to school on how brain activity controls blood flow. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Skin@Bath Network Symposium, December 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Alison Curnow, (along with her collaborators C. Buxton and J. Tyrell) presented findings from her project funded by PMEI titled "The Mechanism of Action of Dermatological PDT" at the Skin@Bath Network Symposium, 14th December 2017 in Bath, UK. |
| Year(s) Of Engagement Activity | 2017 |
| Description | The 8th Clinical Genomic Analysis workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | 8th June 2017. This is an international annual healthcare conference held by IBM Research in Israel. It was focussed on the analysis of disease-related big data. Our researcher Dr Piotr Slowinski attended and gave a talk entitled 'Biomedical applications of the earth mover's distance - from individual motor signature to integrated RNA-DNA allelic maps'. Outputs associated with this are as follows: sharing our research, networking with other researchers, invited speakers and industry working in the healthcare field, potential for new collaborations, meeting members of IBM Research and understanding how IBM Research works |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.research.ibm.com/haifa/Workshops/cga2017/ |
| Description | Workshop with Omani clinical and academic collaborators |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop with Omani clinical and academic collaborators held in Exeter which involved discussion around developing a database of regional pathogenic variants, 2018 |
| Year(s) Of Engagement Activity | 2018 |
| Description | Workshop with Pakistani clinical and academic collaborators |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop with Pakistani clinical and academic collaborators held in Exeter which involved discussion around developing a database of regional pathogenic variants, 2017 |
| Year(s) Of Engagement Activity | 2017 |